Is CERo Therapeutics Holdings, Inc. (CERO) a Buy, Sell, or Hold?
OTC : CERO
CERo Therapeutics Holdings, Inc.
$0.012 USD
$0.0 (-7.69%)
- Volume
- 0
- Average Volume
- 914.2K
- Market Capitalization
- $14.46K
- P/E Ratio
- 0.00
- Dividend Yield
- 0.00%
- Price Target
- Year High
- $8.90
- Year Low
- $0.01
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $0.14
| Source | Headline |
|---|---|
|
CERo Therapeutics Announces Clinical Update from CERTAIN-T Phase 1 CER-1236 Trial, Including Patient Undergoing Allogeneic Stem Cell Transplant Following Treatment
Fifth patient treated with CER-1236 underwent stem cell transplant following lack of response to prior therapies; Company initiates third planned cohort in ongoing Phase 1 study in hematologic malignancies globenewswire.com - 2026-06-15 08:15:00 |
|
CERo Therapeutics Announces Clinical Update from CERTAIN-T Phase 1 CER-1236 Trial, Including Patient Undergoing Allogeneic Stem Cell Transplant Following Treatment
Fifth patient treated with CER-1236 underwent stem cell transplant following lack of response to prior therapies; Company initiates third planned cohort in ongoing Phase 1 study in hematologic malignancies SOUTH SAN FRANCISCO, Calif, June 15, 2026 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. globenewswire.com - 2026-06-15 08:15:00 |
|
CERo Therapeutics Completes Second Ascending Dose Cohort of Phase 1 CER-1236 Trial
Company to initiate third planned cohort at higher dose level, including patients with myelodysplastic syndrome and myelofibrosis globenewswire.com - 2026-05-11 08:15:00 |
|
CERo Therapeutics Completes Second Ascending Dose Cohort of Phase 1 CER-1236 Trial
Company to initiate third planned cohort at higher dose level, including patients with myelodysplastic syndrome and myelofibrosis SOUTH SAN FRANCISCO, Calif. , May 11, 2026 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (OTCQB: CERO) ("CERo" or the "Company"), an innovative cellular immunotherapy company advancing next-generation engineered T cell therapeutics that employ phagocytic mechanisms, announces that it has completed dosing and the 28-day dose-limiting toxicity ("DLT") assessment period for all three patients in the second cohort of its Phase 1 CERTAIN-T clinical trial of CER-1236 in hematologic malignancies. globenewswire.com - 2026-05-11 08:15:00 |
